A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responses

The standard dosing of the Pfizer/BioNTech BNT162b2 mRNA vaccine validated in clinical trials includes two doses administered three weeks apart. While the decision by some public health authorities to space the doses because of limiting supply has raised concerns about vaccine efficacy, data indicat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:bioRxiv
Autors principals: Tauzin, Alexandra, Nayrac, Manon, Benlarbi, Mehdi, Gong, Shang Yu, Gasser, Romain, Beaudoin-Bussières, Guillaume, Brassard, Nathalie, Laumaea, Annemarie, Vézina, Dani, Prévost, Jérémie, Anand, Sai Priya, Bourassa, Catherine, Gendron-Lepage, Gabrielle, Medjahed, Halima, Goyette, Guillaume, Niessl, Julia, Tastet, Olivier, Gokool, Laurie, Morrisseau, Chantal, Arlotto, Pascale, Stamatatos, Leonidas, McGuire, Andrew T., Larochelle, Catherine, Uchil, Pradeep, Lu, Maolin, Mothes, Walther, Serres, Gaston De, Moreira, Sandrine, Roger, Michel, Richard, Jonathan, Martel-Laferrière, Valérie, Duerr, Ralf, Tremblay, Cécile, Kaufmann, Daniel E., Finzi, Andrés
Format: Artigo
Idioma:Inglês
Publicat: Cold Spring Harbor Laboratory 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7987016/
https://ncbi.nlm.nih.gov/pubmed/33758857
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2021.03.18.435972
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars